Pancreatic Cancer Research

ResearcherNew York UniversityActive in the last 2 years

Ding Ding

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5825-9873; OpenAlex author ID A5100352093. Sources: OpenAlex.

Their work

Papers
28 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
98
Papers, trials and grants by year

2018: 4 papers · 2019: 4 papers · 2020: 3 papers · 2021: 7 papers · 2022: 4 papers · 2023: 5 papers · 2024: none · 2025: none · 2026: 1 paper

Papers 28

  1. The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: a single-arm, phase II… Co-author DOI 10.1038/s41467-026-69294-3↗
  2. Oncologic resection of pancreatic cancer with isolated liver metastasis: Favorable outcomes in select patients. Co-author DOI 10.1002/jhbp.1303↗
  3. Tailoring Adjuvant Chemotherapy to Biologic Response Following Neoadjuvant Chemotherapy Impacts Overall Survival in Pancreatic Cancer. Co-author DOI 10.1007/s11605-022-05476-w↗
  4. Surgical Decision-Making in Pancreatic Ductal Adenocarcinoma: Modeling Prognosis Following Pancreatectomy in the Era of Induction and Neoadjuvant Chemotherapy. Co-author DOI 10.1097/sla.0000000000004915↗
  5. Persistent Circulating Tumor Cells at 1 Year After Oncologic Resection Predict Late Recurrence in Pancreatic Cancer. First author DOI 10.1097/sla.0000000000005708↗
  6. A Delay in Adjuvant Therapy Is Associated With Worse Prognosis Only in Patients With Transitional Circulating Tumor Cells After Resection of Pancreatic Ductal … Co-author DOI 10.1097/sla.0000000000005710↗
  7. Accurate Nodal Staging in Pancreatic Cancer in the Era of Neoadjuvant Therapy. First author DOI 10.1007/s00268-021-06410-y↗
  8. CCR2/CCR5 inhibitor permits the radiation-induced effector T cell infiltration in pancreatic adenocarcinoma. Co-author DOI 10.1084/jem.20211631↗
  9. RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. First author DOI 10.1200/po.21.00404↗
  10. Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10663-1↗
  11. Reliable Detection of Somatic Mutations for Pancreatic Cancer in Endoscopic Ultrasonography-Guided Fine Needle Aspirates with Next-Generation Sequencing: Impli… Co-author DOI 10.1007/s11605-021-05078-y↗
  12. Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017. Co-author DOI 10.1016/j.canlet.2020.10.039↗
  13. Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy. Co-author DOI 10.1016/j.jamcollsurg.2020.11.018↗
  14. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectabl… First author DOI 10.1158/1078-0432.ccr-20-2974↗
  15. An Aggressive Approach to Locally Confined Pancreatic Cancer: Defining Surgical and Oncologic Outcomes Unique to Pancreatectomy with Celiac Axis Resection (DP-… Co-author DOI 10.1245/s10434-020-09201-2↗
  16. Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells. Co-author DOI 10.20892/j.issn.2095-3941.2020.0273↗
  17. Impact of somatic mutations on clinical and pathologic outcomes in borderline resectable and locally advanced pancreatic cancer treated with neoadjuvant chemot… Co-author DOI 10.3857/roj.2021.00815↗
  18. Disparities in the Use of Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s11605-019-04311-z↗
  19. Interrogating the immune-modulating roles of radiation therapy for a rational combination with immune-checkpoint inhibitors in treating pancreatic cancer. Co-author DOI 10.1136/jitc-2019-000351↗
  20. Radical antegrade modular pancreatosplenectomy versus standard distal pancreatosplenectomy for pancreatic cancer, a dual-institutional analysis. Co-author DOI 10.21037/cco-20-6↗
  21. Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy. Co-author DOI 10.1007/s11605-018-3966-8↗
  22. Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer. Co-author DOI 10.1016/j.ejso.2019.04.007↗
  23. Isolated pulmonary recurrence after resection of pancreatic cancer: the effect of patient factors and treatment modalities on survival. Co-author DOI 10.1016/j.hpb.2018.12.002↗
  24. Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-0197↗
  25. Incidence and risk factors for abdominal occult metastatic disease in patients with pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.25288↗
  26. Circulating Tumor Cells Dynamics in Pancreatic Adenocarcinoma Correlate With Disease Status: Results of the Prospective CLUSTER Study. Co-author DOI 10.1097/sla.0000000000002925↗
  27. Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer. Co-author DOI 10.1186/s40425-018-0435-6↗
  28. Implications of the Pattern of Disease Recurrence on Survival Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6558-7↗

Closest collaborators

The 25 strongest of 98 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jin Peng He · 22 shared papers, 2018–2023 · strength 2.33
  2. Richard Andrew Burkhart · 19 shared papers, 2018–2026 · strength 2.15
  3. Ammar A. Javed · 17 shared papers, 2018–2023 · strength 1.95
  4. Christopher Lee Wolfgang · 16 shared papers, 2018–2023 · strength 1.62
  5. William R. Burns · 11 shared papers, 2021–2023 · strength 1.42
  6. Lei Zheng · 13 shared papers, 2018–2026 · strength 1.41
  7. Matthew John Weiss · 14 shared papers, 2018–2023 · strength 1.30
  8. Kelly J. Lafaro · 8 shared papers, 2021–2026 · strength 1.17
  9. Michael J. Wright · 10 shared papers, 2019–2023 · strength 1.10
  10. Amol Kumar Narang · 9 shared papers, 2019–2026 · strength 1.02
  11. Alex B. Blair · 11 shared papers, 2018–2022 · strength 0.96
  12. Jun Yu · 9 shared papers, 2018–2023 · strength 0.91
  13. Christopher L. Wolfgang · 7 shared papers, 2021–2023 · strength 0.90
  14. Daniel A. Laheru · 8 shared papers, 2019–2026 · strength 0.84
  15. Georgios Gemenetzis · 9 shared papers, 2018–2023 · strength 0.81
  16. Vincent P. Groot · 9 shared papers, 2018–2023 · strength 0.81
  17. Ralph H. Hruban · 6 shared papers, 2018–2023 · strength 0.62
  18. Joseph M. Herman · 5 shared papers, 2019–2026 · strength 0.61
  19. Elliot K. Fishman · 6 shared papers, 2018–2022 · strength 0.51
  20. Robert A. Anders · 4 shared papers, 2021–2026 · strength 0.46
  21. Dung Thi Le · 4 shared papers, 2021–2026 · strength 0.46
  22. Elizabeth M. Jaffee · 4 shared papers, 2018–2026 · strength 0.44
  23. Joseph R. Habib · 3 shared papers, 2021–2023 · strength 0.42
  24. Richard A. Burkhart · 3 shared papers, 2020–2023 · strength 0.41
  25. Alina Hasanain · 3 shared papers, 2019–2023 · strength 0.40

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.